STOCK TITAN

Establishment Labs Reports First Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported first quarter 2024 financial results, with worldwide revenue of $37.2 million. The 2024 revenue guidance is $174 million to $184 million, reflecting a 5% to 11% increase over 2023. Gross profit was $24.4 million, with a loss from operations of $8.8 million. Adjusted EBITDA loss improved to $3.7 million. The company's cash balance was $73.0 million as of March 31, 2024. Establishment Labs presented 4-year results from Motiva® U.S. IDE study showing positive outcomes, aiming for FDA approval of Motiva Implants in 2024.

Positive
  • Global medical technology company, Establishment Labs, reported a 2024 first quarter revenue of $37.2 million, showcasing a stable market demand and positive growth outlook.

  • Significant steps taken to reduce expense base resulted in improved adjusted EBITDA loss to less than $4 million, reflecting a positive trend towards financial stability.

  • Presented 4-year results from Motiva® U.S. IDE study, demonstrating low rates of capsular contracture and rupture, setting new standards for breast implants, enhancing market reputation.

  • Continued progress towards FDA approval of Motiva Implants in the U.S., indicating potential revenue growth in 2024.

Negative
  • Net loss for the first quarter was $16.2 million compared to a net loss of $11.9 million in the year-ago period, indicating a decline in profitability.

  • Total revenue decreased to $37.2 million from $46.5 million for the same period in 2023, signaling a revenue decline potentially impacting shareholder confidence.

  • R&D expenses decreased to $4.3 million, highlighting a reduction in research and development investments that may impact future product innovation.

Insights

Establishment Labs' first quarter revenue of $37.2 million signals a decrease from the previous year's $46.5 million, yet the company maintains a revenue guidance signaling optimism with an anticipated 5% to 11% growth. The gross profit margin incrementally improved, suggesting effective cost management despite the revenue dip. However, a net loss increase to $16.2 million could raise investor concerns, reflecting potential scaling costs or market challenges. The firm’s cash position, bolstered by a private placement, offers some liquidity assurance. The forecasted FDA approval for Motiva Implants is poised to be a critical driver for future growth, given the product's promising clinical trial results. While current financial performance shows mixed signals, the strategic expansion and product pipeline provide potential long-term value.

The report highlights Establishment Labs' strategic initiatives, such as launching Motiva implants in China and the Flora tissue expander in the US. The expansion into new geographical markets and product categories can diversify revenue streams and mitigate risks associated with single-market dependence. In the highly competitive med-tech landscape, such innovation is key for differentiation and long-term growth. The emphasis on R&D investment, despite overall cost reduction, aligns with sustaining competitive advantage through innovation. Moreover, the impending FDA approval and expected US launch of Motiva Implants could unlock a significant market, contributing positively to future revenue given the favorable study results presented. Investors should monitor the company's progress in these areas against market adoption rates and regulatory developments.

Establishment Labs' extensive patent portfolio, with over 200 patent applications, underscores a robust intellectual property strategy important in the medical technology sector. This portfolio not only protects their innovations but also lays the groundwork for potential licensing opportunities, which could represent an additional revenue stream. The presented clinical trial results reinforce the value proposition of their products, potentially enhancing patent strength. Investors with interest in med-tech innovation should consider the implications of a strong patent portfolio as a defensive moat against competition, as well as its role in facilitating international expansion efforts.

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.

First Quarter Highlights and Outlook

  • First quarter worldwide revenue of $37.2 million.
  • 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants® in the United States, which is expected in 2024.
  • Gross profit for the first quarter was $24.4 million, or 65.6% of revenue, compared to $30.1 million, or 64.7% of revenue, in the year-ago period.
  • First quarter loss from operations was $8.8 million compared to a loss of $22.1 million in the fourth quarter of 2023 and $8.2 million in the year-ago period.
  • Adjusted EBITDA loss of $3.7 million compared to a loss of $17.3 million in the fourth quarter of 2023 and a loss of $4.0 million in the year-ago period.
  • Cash balance of $73.0 million as of March 31, 2024.
  • Presented 4-year results from Motiva® U.S. IDE study at The Aesthetic Meeting on May 2.
  • Continued progress with FDA on approval of Motiva Implants.

“We are off to a strong start in 2024. Market demand is stabilizing, and we expect to see continued improvement over the course of the year. We have taken meaningful steps to reduce our expense base and our adjusted EBITDA improved significantly to a loss of less than $4 million,” said Juan José Chacón-Quirós, Chief Executive Officer. “Over the past several months, we launched Motiva implants in China as well as our Flora tissue expander in the United States. The number of clinics offering Mia around the world is growing and we are seeing strong evidence that Mia is opening an entirely new and market expanding category in breast aesthetics.”

“Last week, four-year data from the Motiva US IDE study was presented at the Aesthetic Meeting in Vancouver. The very low rates of capsular contracture and rupture shown at year two remained unchanged through year four, and the results set a completely new standard for breast implants,” Mr. Chacón-Quirós continued. “We expect U.S. FDA approval of Motiva this year and we have made several key hires as we prepare for the launch. We are on a clear path for global market leadership and have many years of strong and healthy growth ahead of us.”

First Quarter 2024 Financial Results

Total revenue for the quarter ended March 31, 2024 was $37.2 million compared to $46.5 million for the same period in 2023.

Gross profit for the first quarter was $24.4 million, or 65.6% of revenue, compared to $30.1 million, or 64.7% of revenue, for the same period in 2023. The increase in gross profit margin was primarily driven by geographic mix and higher average selling prices.

Total operating expenses for the first quarter were $33.2 million, a decrease of $5.0 million compared to $38.2 million in the first quarter of 2023.

SG&A expenses for the first quarter decreased approximately $2.8 million to $28.9 million compared to $31.7 million in the first quarter of 2023. The decrease in SG&A was primarily the result of the cost reduction initiatives, including headcount reductions.

R&D expenses decreased approximately $2.2 million to $4.3 million in the first quarter compared to $6.5 million for the same quarter a year ago. The decrease was primarily due to reductions in personnel costs.

Net loss for the first quarter was $16.2 million compared to a net loss of $11.9 million in the year ago period.

The Company’s cash balance on March 31, 2024 was $73.0 million. Cash increased $32.9 million from December 31, 2023, primarily as a result of the private placement offering completed on January 9 partially offset by operating losses and investments in the new manufacturing facility.

Conference Call and Webcast Information

Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (international) and using conference ID number 13742370. In addition, the live and archived webcast will be available on the Investor Relations section of the Company's website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.

Establishment Labs' Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States. The Company’s implants are undergoing PMA clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.

Non-GAAP Financial Measures

To supplement our financial results presented in accordance with GAAP, this release includes the following measures defined by the Securities and Exchange Commission as non-GAAP financial measures: EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies, limiting the usefulness of the measures for comparison with other companies.

EBITDA is defined as net income or loss excluding: (1) interest expense; (2) provision for income taxes; and (3) depreciation and amortization. We consider EBITDA useful to an investor in evaluating and facilitating comparisons of our operating performance between periods by removing the impact of our capital structure (primarily interest expense) and asset base (primarily depreciation and amortization) from our operating results.

We also present Adjusted EBITDA which includes additional adjustments for items such as other non-cash charges, gains or losses on extinguishment of debt, share-based compensation and foreign currency gains and losses. We believe that Adjusted EBITDA provides useful supplemental information to investors regarding our ongoing operating performance that, when considered with net income and EBITDA, is beneficial to an investor's understanding of our performance.

We believe disclosure of this information is also useful to investors as it provides insight into the earnings that management uses to make strategic decisions. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income or loss as prescribed by GAAP as a measure of our operating performance. EBITDA and Adjusted EBITDA do not represent cash generated from operating activities under GAAP and should not be considered as alternatives to cash flows from operations or any other operating performance measure prescribed by GAAP. These measures are not measures of our liquidity, nor are indicative of funds available to fund our cash needs. These measurements do not reflect cash expenditures for long-term assets and other items that have been and will be incurred. EBITDA and Adjusted EBITDA may include funds that may not be available for management’s discretionary use due to functional requirements to conserve funds for capital expenditures, property acquisitions, and other commitments and uncertainties.

Please see “Reconciliation of EBITDA and Adjusted EBITDA” for a reconciliation of these measures to net income (loss), the most directly comparable financial measure. This release also includes information about our expectations regarding Adjusted EBITDA on a forward-looking basis. We have not provided a reconciliation of such forward-looking Adjusted EBITDA information because a reconciliation of such measure to our expected GAAP net income (loss) on a forward-looking basis is not available without unreasonable efforts. The timing or amount of various reconciling items that would impact the forward-looking expectations for this non-GAAP financial measure are uncertain, depend on various factors and cannot be reasonable predicted. Such unavailable information could be material to our results computed in accordance with U.S. GAAP.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on March 4, 2024 and will be discussed in the company's quarterly report on Form 10-Q that will be filed on May 9, 2024, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

ESTABLISHMENT LABS HOLDINGS INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

 

 

 

 

 

 

Three Months Ended
March 31,

 

 

 

2024

 

 

 

2023

 

Revenue

 

$

37,167

 

 

$

46,524

 

Cost of revenue

 

 

12,787

 

 

 

16,445

 

Gross profit

 

 

24,380

 

 

 

30,079

 

Operating expenses:

 

 

 

 

Sales, general and administrative

 

 

28,941

 

 

 

31,706

 

Research and development

 

 

4,273

 

 

 

6,533

 

Total operating expenses

 

 

33,214

 

 

 

38,239

 

Loss from operations

 

 

(8,834

)

 

 

(8,160

)

Interest income

 

 

488

 

 

 

75

 

Interest expense

 

 

(4,381

)

 

 

(3,756

)

Other income (expense), net

 

 

(3,037

)

 

 

729

 

Loss before income taxes

 

 

(15,764

)

 

 

(11,112

)

Provision for income taxes

 

 

(438

)

 

 

(830

)

Net loss

 

$

(16,202

)

 

$

(11,942

)

 

 

 

 

 

Basic and diluted net loss per share

 

$

(0.58

)

 

$

(0.48

)

Weighted average outstanding shares used for basic and diluted net loss per share

 

 

27,788,120

 

 

 

24,678,113

 

 
 

ESTABLISHMENT LABS HOLDINGS INC.

Consolidated Balance Sheets

(In thousands)

 

 

 

 

 

March 31,
2024

 

December 31,
2023

 

(Unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash

$

72,980

 

$

40,035

Accounts receivable, net of allowance for doubtful accounts of $2,014 and $1,841

 

50,838

 

 

46,918

Inventory, net

 

72,489

 

 

79,471

Prepaid expenses and other current assets

 

7,388

 

 

8,477

Total current assets

 

203,695

 

 

174,901

Long-term assets:

 

 

 

Property and equipment, net of accumulated depreciation

 

79,244

 

 

77,205

Goodwill

 

465

 

 

465

Intangible assets, net of accumulated amortization

 

9,515

 

 

7,987

Right-of-use operating lease assets, net

 

3,908

 

 

3,381

Other non-current assets

 

5,011

 

 

4,702

Total assets

$

301,838

 

$

268,641

Liabilities and shareholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

31,070

 

$

41,624

Accrued liabilities

 

15,207

 

 

13,690

Other liabilities, short-term

 

1,739

 

 

1,836

Total current liabilities

 

48,016

 

 

57,150

Long-term liabilities:

 

 

 

Note payable, net of debt discount and issuance costs

 

192,186

 

 

188,739

Operating lease liabilities, non-current

 

3,180

 

 

2,712

Other liabilities, long-term

 

1,545

 

 

1,645

Total liabilities

 

244,927

 

 

250,246

Shareholders’ equity:

 

 

 

Total shareholders’ equity

 

56,911

 

 

18,395

Total liabilities and shareholders’ equity

$

301,838

 

$

268,641

 
 

Reconciliation of EBITDA and Adjusted EBITDA

The following is a reconciliation of net loss to EBITDA and Adjusted EBITDA:

 

Three Months Ended March 31,

 

 

2024

 

 

 

2023

 

 

 

 

 

Net loss

$

(16,202

)

 

$

(11,942

)

Interest expense

 

(4,381

)

 

 

(3,756

)

Provision for income taxes

 

(438

)

 

 

(830

)

Depreciation and amortization

 

(1,268

)

 

 

(936

)

EBITDA

 

(10,115

)

 

 

(6,420

)

Stock compensation expense

 

(3,444

)

 

 

(3,324

)

Foreign currency gains (losses)

 

(3,019

)

 

 

919

 

Adjusted EBITDA

$

(3,652

)

 

$

(4,015

)

 

 

 

 

 

Investor/Media Contact:

Raj Denhoy

415 828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

What was Establishment Labs' first quarter revenue for 2024?

Establishment Labs reported a first quarter revenue of $37.2 million for 2024.

What is Establishment Labs' 2024 revenue guidance?

Establishment Labs' 2024 revenue guidance is $174 million to $184 million, representing a 5% to 11% increase over 2023.

What was the gross profit and loss from operations for the first quarter of 2024?

The gross profit for the first quarter was $24.4 million, with a loss from operations of $8.8 million.

What was the cash balance of Establishment Labs as of March 31, 2024?

Establishment Labs' cash balance was $73.0 million as of March 31, 2024.

What significant study results did Establishment Labs present?

Establishment Labs presented 4-year results from the Motiva® U.S. IDE study, showcasing positive outcomes such as low rates of capsular contracture and rupture.

Establishment Labs Holdings Inc.

NASDAQ:ESTA

ESTA Rankings

ESTA Latest News

ESTA Stock Data

1.31B
27.94M
11.3%
90.5%
18.91%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ALAJUELA